

XTENT INC  
Form 8-K  
June 04, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

---

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**June 3, 2009**

Date of Report (date of earliest event reported)

**XTENT, INC.**

(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**001-33282**  
(Commission File Number)

**41-2047573**  
(I.R.S. Employer  
Identification Number)

**125 Constitution Drive**  
**Menlo Park, California 94025-1118**

(Address of principal executive offices)

Edgar Filing: XTENT INC - Form 8-K

(650) 475-9400

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On June 3, 2009, the board of directors of XTENT, Inc. (the Company ) set July 9, 2009 as the date for the special meeting of the Company s stockholders at which stockholders will vote on a plan of complete liquidation and dissolution of the Company.

On June 4, 2009, the Company issued a press release announcing that the U.S. Food and Drug Administration has granted conditional approval of the Company s pivotal clinical program for its Custom NX Drug Eluting Stent System. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of XTENT, Inc. dated as of June 4, 2009.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**XTENT, INC.**

Date: June 4, 2009

By:

/s/ Gregory D. Casciaro  
Gregory D. Casciaro  
President & Chief Executive Officer